{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
4D Molecular Therapeutics, Inc.
Is 4D Molecular Therapeutics, Inc. overvalued or undervalued?
As of February 28, 2025, 4D Molecular Therapeutics, Inc. is assessed as overvalued and has deteriorated to a "does not qualify" valuation grade due to negative financial metrics, poor stock performance, and significant contrasts with peers.
Is 4D Molecular Therapeutics, Inc. technically bullish or bearish?
As of June 17, 2025, the technical trend has shifted to mildly bearish, driven by daily moving averages and monthly MACD indicators, despite some weekly bullish signals.
What does 4D Molecular Therapeutics, Inc. do?
4D Molecular Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 and a net loss of $48 million as of March 2025. The company has a market cap of $192.25 million and key metrics indicate it is currently loss-making with no dividend yield.
How big is 4D Molecular Therapeutics, Inc.?
As of Jun 18, 4D Molecular Therapeutics, Inc. has a market capitalization of 192.25 million, with net sales of 0.02 million and a net profit of -176.43 million over the latest four quarters. The company has shareholder's funds of 510.61 million and total assets of 560.38 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
